Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 10/20 | 1.00 |
| ▸ | CDC25A | P30304 | 7/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 6/20 | 1.00 |
| ▸ | S100A4 | P26447 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | APAF1 | O14727 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | TDP2 | O95551 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527717 | 1.00 | CDC25B (1.00) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL2599362 | 0.83 | CDC25B (1.00) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL15630378 | 0.83 | CDC25B (0.70) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL2599202 | 0.81 | CDC25B (1.00) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL9437128 | 0.81 | CDC25B (0.68) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL17249980 | 0.80 | CDC25B (0.73) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL6801767 | 0.79 | CDC25B (0.65) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL16884403 | 0.78 | CDC25B (0.70) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL2599346 | 0.75 | CDC25B (1.00) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 | |
| SCHEMBL29531175 | 0.75 | CDC25B (1.00) | CDC25BCDC25AMAP2K7S100A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891363-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | King Faisal University (SA) | 2024-02-06 | — | — | US | claimed |
| WO-1998027970-A2 | TREATMENT OF DISEASES OR PREVENTION OF CELLULAR DAMAGE CAUSED BY OXYGEN-CONTAINING FREE RADICALS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1998-07-02 | — | — | WO | claimed |
| US-12611398-B2 | Inhalable rapamycin formulation for the treatment of pulmonary hypertension | ORPHAI THERAPEUTICS INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12576037-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250339654-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250295841-A1 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | UROTRONIC, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12383710-B2 | Drug-coated balloon catheters for body lumens | UROTRONIC, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12357732-B2 | Drug coated balloon catheters for nonvascular strictures | UROTRONIC, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250213755-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250213491-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250213827-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2014045783-A1 | ORIGINAL PLANOGRAPHIC PRINTING PLATE, AND PLATE MAKING METHOD | 富士フイルム株式会社 (JP) | 2014-03-27 | — | — | WO | disclosed |
| WO-2003066110-A1 | PATHOGEN REDUCTION SOLUTION FOR PLATELETS CONTAINING AN ENDOGENOUS PHOTOSENSITIZER AND A GLYCOLYSIS INHIBITOR. | GAMBRO, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-6322776-B1 | Anhydrous high-SPF ultraviolet light screens | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. | 2001-11-27 | — | — | US | disclosed |
| WO-2000078278-A1 | ANHYDROUS ULTRAVIOLET LIGHT SCREENING COMPOSITION CONTAINING OCTOCRYLENE | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1060735-A1 | Anhydrous ultraviolet light screening composition containing octocrylene | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1998027970-A2 | TREATMENT OF DISEASES OR PREVENTION OF CELLULAR DAMAGE CAUSED BY OXYGEN-CONTAINING FREE RADICALS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1998-07-02 | — | — | WO | disclosed |
| EP-0552223-A1 | USE OF BENZENE DERIVATIVES AS CHARGE TRANSFER MEDIATORS. | NOVO NORDISK AS (DK) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992007263-A1 | USE OF BENZENE DERIVATIVES AS CHARGE TRANSFER MEDIATORS | NOVO NORDISK A/S (DK) | 1992-04-30 | — | — | WO | disclosed |
| EP-0146338-A2 | A blood accelerator 2, 3-diphosphoglyceric acid | SHIRATORI PHARMACEUTICAL CO. LTD. (JP) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576037-B2 | Polymer-encapsulated drug particles | PHOSPHO1, SGMS1, SGMS2 | CDC25B 4200/4885CDC25A 3988/4885MAP2K7 2515/4885 |
| US-11891363-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | BRCA1, HSP90AB1, HSF1 | CDC25B 3417/4885CDC25A 3290/4885MAP2K7 330/4885 |
| US-20250213491-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | CD47, GRPR, HSPA5 | CDC25B 4466/4885CDC25A 4587/4885MAP2K7 3103/4885 |
| US-12611398-B2 | Inhalable rapamycin formulation for the treatment of pulmonary hypertension | RICTOR, MTOR, RPTOR | CDC25B 1780/4885CDC25A 1351/4885MAP2K7 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.